
500 experts at the 7th AMR Conference in Basel
That antimicrobial resistance can no longer be considered a silent pandemic became abundantly clear at the AMR Conference in Basel from March 16-17....

Novartis in US$465m deal with 3B Pharmaceuticals GmbH
Under the agreement, which foresees US$425m in milestones plus royalities on future sales for 3B Pharmaceuticals GmbH (3BP), Basel-based pharma...

Forbion raises €1.35bn across two funds
Both funds, the early stage Forbion Ventures Fund VI (€750m) and the Forbion Growth Opportunities Fund II (€600m), which will invest up to €70m in up...

Dualyx NV raises €40m in Series A financing
The Series A financing was co-led by Fountain Healthcare Partners, Forbion and Andera Partners and seed investors V-Bio Ventures, BGV, PMV, VIB,...

Roche’s meets endpoints in relapsing multiple sclerosis
In patients with relapsing-remitting multiple sclerosis (RRMS), fenebrutinib significantly reduced the total number of new gadolinium-enhancing...

Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour
The latest Swiss Biotech Report, published at the end of April by the Swiss Biotech Association (SBA) in collaboration with EY and eight other...

Researchers activate chemotherapeutics by ultrasound
Chemotherapeutic treatments produce strong side effects. A new drug complex that accumulates in the tumour tissue and is only activated there by...